Last updated: October 29, 2026
NovoLog Mix 50/50 is a mature premixed insulin product containing 50% insulin aspart and 50% insulin aspart protamine suspension. Novo Nordisk markets it in the United States for mealtime and intermediate insulin coverage. Its commercial trajectory is constrained by product maturity, low-cost human insulin alternatives, biosimilar and follow-on insulin competition, and the shift toward basal-bolus analog regimens and GLP-1 medicines. Novo Nordisk does not separately disclose NovoLog Mix 50/50 revenue, prescription volume, or operating profit.
What is NovoLog Mix 50/50 and how does it work?
NovoLog Mix 50/50 is a U-100 injectable premix containing equal proportions of rapid-acting insulin aspart and a longer-acting protamine formulation of insulin aspart. The rapid-acting component addresses postprandial glucose, while the protamine component provides intermediate-duration coverage.[1]
The product is administered subcutaneously shortly before meals. Its fixed ratio limits dose flexibility compared with separate basal and mealtime insulin products. That limitation is commercially relevant because many patients and prescribers increasingly favor individualized basal-bolus treatment or combination therapy involving GLP-1 receptor agonists.
| Product attribute |
NovoLog Mix 50/50 |
| Active ingredients |
Insulin aspart and insulin aspart protamine suspension |
| Strength |
100 units/mL |
| Premix ratio |
50% rapid-acting, 50% intermediate-acting |
| Sponsor |
Novo Nordisk |
| U.S. regulatory application |
NDA 021551 |
| Administration |
Subcutaneous injection |
| Primary use |
Mealtime and intermediate insulin coverage in diabetes |
| Main competitors |
NovoLog Mix 70/30, Humalog Mix75/25, human premixed insulin, separate basal-bolus analogs |
| U.S. revenue disclosure |
Not reported separately by Novo Nordisk |
NovoLog Mix 50/50 is distinct from NovoLog Mix 70/30, which contains a larger proportion of the protamine component. The 50/50 ratio may be selected when a patient needs greater prandial insulin exposure than the 70/30 formulation provides.
When did NovoLog Mix 50/50 receive FDA approval?
The FDA approved NovoLog Mix 50/50 under NDA 021551 in 2007. The product belongs to the insulin aspart family, which includes NovoLog and NovoLog Mix 70/30.[1]
The product’s FDA label establishes its use in adults with diabetes mellitus. Unlike a new molecular entity, NovoLog Mix 50/50 entered the market as a reformulated and ratio-specific insulin aspart product. Its commercial value therefore depended more on delivery convenience, dosing preference, physician familiarity, and formulary access than on long-term new-drug exclusivity.
What is the FDA regulatory status of NovoLog Mix 50/50?
NovoLog Mix 50/50 is an FDA-approved insulin product. Insulin products historically approved under the Federal Food, Drug, and Cosmetic Act transitioned to the Public Health Service Act biologics framework in March 2020. FDA treats insulin products as biologics for purposes of the modern biosimilar and interchangeable-product pathway.[2]
The product’s regulatory position is different from that of a conventional small-molecule generic. A competing manufacturer can pursue an abbreviated pathway based on reference-product data, including a biosimilar or interchangeable insulin route where applicable. FDA approval does not automatically provide pharmacy-level substitution; interchangeability and state substitution laws can affect actual market uptake.
What patents protect NovoLog Mix 50/50?
The principal intellectual-property value of NovoLog Mix 50/50 was historically associated with insulin aspart, protamine suspension technology, formulation know-how, manufacturing processes, device configuration, and regulatory exclusivity. The core commercial period for the product is long past.
Publicly available FDA materials do not provide a single definitive “last patent expiration” date for the complete NovoLog Mix 50/50 commercial package. FDA approval records and product labeling identify the product and its NDA, but they do not establish that every formulation, manufacturing, device, or process patent has the same expiration date.[1]
The core insulin aspart composition has been public for many years, and the principal composition-related patent protection is no longer the primary barrier to competition. Any remaining protection is more likely to involve specific formulations, manufacturing processes, delivery devices, or regulatory and commercial barriers than broad compound exclusivity.
What formulation patents protect premixed insulin aspart?
Formulation protection can cover:
- The ratio of soluble insulin aspart to protamine-complexed insulin aspart.
- Particle size, suspension stability, and resuspension characteristics.
- Preservatives, excipients, pH, and storage conditions.
- Manufacturing steps that produce consistent rapid-acting and intermediate-acting fractions.
- Pen, vial, cartridge, and injection-device configurations.
These rights can complicate product development, but they generally do not prevent a competitor from pursuing a non-infringing premix or a different insulin delivery format. Manufacturing know-how may be more commercially important than a single surviving formulation patent because premixed insulin requires consistent suspension performance and dose uniformity.
When does NovoLog Mix 50/50 lose exclusivity?
NovoLog Mix 50/50 has already passed the period in which FDA regulatory exclusivity would be the main competitive barrier. Its market protection is now determined by the remaining patent position, manufacturing capability, FDA approval pathways, contracts, rebates, and pharmacy substitution rules.
For a mature insulin product, loss of exclusivity does not necessarily produce immediate generic erosion. Entry depends on whether a competitor can achieve:
- FDA approval through an appropriate insulin or biosimilar pathway.
- Reliable commercial-scale manufacturing.
- Acceptable device and container compatibility.
- Payer and pharmacy access.
- Sufficient price advantage after rebates and discounts.
- Prescriber confidence in switching between premixed products.
How many patents cover NovoLog Mix 50/50?
No reliable public source establishes a current, product-specific count of all U.S. patents covering NovoLog Mix 50/50. A patent count based only on Orange Book entries would understate the relevant estate because insulin protection may involve biologic, formulation, process, device, and manufacturing rights outside a narrow product-listing analysis.
The practical conclusion is that NovoLog Mix 50/50 has a low remaining composition-patent barrier but may still carry process and formulation sensitivities. Patent risk is materially lower than for a recently launched biologic with active composition and use patents.
What is the Orange Book status of NovoLog Mix 50/50?
NovoLog Mix 50/50 was approved under an NDA, but insulin’s 2020 transition into the biologics framework changed how future competing products are likely to be regulated. The Orange Book remains relevant to legacy NDA information, but biosimilar competition is principally associated with the Purple Book and the Public Health Service Act pathway.[2,3]
For commercial diligence, the following distinction matters:
| Issue |
NovoLog Mix 50/50 implication |
| Legacy FDA approval |
NDA-based approval |
| Current biologic framework |
Insulin regulated as a biologic |
| Conventional ANDA substitution |
Not the only relevant route |
| Biosimilar pathway |
Potentially available for competing insulin products |
| Interchangeability |
Separate FDA designation affecting substitution |
| Patent litigation |
May involve patents outside a simple Orange Book review |
What patent litigation affects NovoLog Mix 50/50?
No major publicly reported U.S. patent litigation directed specifically at NovoLog Mix 50/50 is identified in the cited FDA and Novo Nordisk materials. The product is commercially mature, and litigation risk is more likely to arise from a new entrant’s product, manufacturing process, device, or formulation than from a basic challenge to insulin aspart composition rights.
A Paragraph IV challenge could still arise if a competitor files an abbreviated application that addresses patents listed against a relevant reference product. For a biologic insulin, however, the principal competitive route may involve the biosimilar patent dance under the Biologics Price Competition and Innovation Act rather than a conventional Paragraph IV case.
Which companies are challenging NovoLog Mix 50/50?
No company is identified in the cited public sources as having launched a product specifically substitutable for NovoLog Mix 50/50 through a publicly documented patent challenge. The broader insulin competitive field includes Eli Lilly, Sanofi, Biocon, Viatris, and other manufacturers, but their insulin products do not automatically compete on a one-for-one basis with a 50/50 premix.
What is the financial trajectory of NovoLog Mix 50/50?
NovoLog Mix 50/50 is a mature, non-strategic revenue line relative to Novo Nordisk’s obesity and diabetes growth products. Novo Nordisk does not report financial results for the product separately. Its sales are included within broader insulin or diabetes-care reporting categories.[4]
The product’s likely financial profile is:
- Low incremental growth.
- Stable demand among established users.
- Pricing pressure from formularies and government programs.
- Declining strategic priority relative to GLP-1 medicines.
- Limited visibility into product-level margin and revenue.
- Potential volume erosion from basal-bolus analogs and non-insulin therapies.
Novo Nordisk reported total 2024 sales of DKK 290.4 billion, compared with DKK 232.3 billion in 2023. The company’s growth was driven primarily by Ozempic, Wegovy, and related GLP-1 products rather than mature premixed insulin brands.[4] Those companywide figures do not support a product-specific NovoLog Mix 50/50 revenue estimate.
What revenue exposure does NovoLog Mix 50/50 represent for Novo Nordisk?
The exposure is immaterial to Novo Nordisk’s consolidated financial statements unless the product experiences a major supply disruption or a sharp loss of formulary access. Novo Nordisk does not publish a separate sales line for NovoLog Mix 50/50, so assigning a precise percentage of company revenue would be speculative.
The product remains relevant in three narrower areas:
- It supports the company’s insulin portfolio and physician relationships.
- It provides an option for patients requiring a fixed premix ratio.
- It contributes recurring revenue from an established treatment category.
Its strategic value is greater as part of portfolio completeness than as a growth driver.
How does NovoLog Mix 50/50 compare with competing insulin products?
| Product |
Manufacturer |
Premix ratio |
Competitive position |
| NovoLog Mix 50/50 |
Novo Nordisk |
50% rapid / 50% protamine |
Narrower, prandial-heavy premix option |
| NovoLog Mix 70/30 |
Novo Nordisk |
30% rapid / 70% protamine |
More established premix alternative |
| Humalog Mix75/25 |
Eli Lilly |
25% rapid / 75% protamine |
Direct analog premix competitor |
| Human insulin 70/30 |
Multiple manufacturers |
30% regular / 70% NPH |
Lower-cost alternative |
| Separate basal and mealtime insulin |
Multiple manufacturers |
Flexible |
Greater dosing flexibility |
| GLP-1-based regimens |
Novo Nordisk, Eli Lilly and others |
Not insulin premix |
Increasing substitution pressure in type 2 diabetes |
NovoLog Mix 50/50 has a differentiated ratio but a smaller addressable market than the widely used 70/30 products. Its principal advantage is a familiar analog formulation with a higher rapid-acting share. Its principal disadvantage is reduced flexibility and the need to manage meal timing closely.
What generic and biosimilar launch risks exist?
The risk is moderate over the long term but limited by market complexity. A competing insulin aspart premix could pressure NovoLog Mix 50/50 through lower pricing, payer contracting, and pharmacy substitution if the competitor obtains an interchangeable designation.
The main barriers are manufacturing and market access rather than basic scientific feasibility. A competitor must reproduce clinical performance, suspension characteristics, device functionality, storage conditions, and batch consistency. It must also convince payers that switching produces meaningful savings.
A generic launch would most likely follow one of three paths:
- A biosimilar or interchangeable insulin aspart premix.
- A non-identical premix with a different ratio or device.
- A lower-cost human insulin product that captures price-sensitive patients.
The first path presents the most direct threat. The third may create the greatest volume pressure in government and cash-pay segments.
How strong is the NovoLog Mix 50/50 patent estate?
The estate is weak to moderate as a current exclusivity asset. Broad composition protection is mature, and the product has been marketed for many years. Process, formulation, and device patents can still impose development costs, but they are unlikely to create a durable monopoly by themselves.
| Factor |
Assessment |
| Core composition exclusivity |
Weak due to product maturity |
| Formulation protection |
Potentially meaningful, depending on claim scope and expiry |
| Manufacturing know-how |
Meaningful operational barrier |
| Device protection |
Relevant but avoidable through alternative devices |
| Regulatory exclusivity |
Expired or no longer the main barrier |
| Biosimilar entry risk |
Moderate |
| Near-term revenue durability |
Moderate, supported by installed use |
| Long-term growth |
Low |
What are the geographic market dynamics?
NovoLog Mix 50/50 is primarily a U.S.-relevant product. Premixed insulin products are marketed differently across jurisdictions, and availability, naming, reimbursement, and regulatory status vary by country.
The United States has the strongest potential for follow-on insulin competition because of its large insulin market, established payer formularies, and FDA biosimilar framework. European markets may apply stronger centralized pricing controls and tender mechanisms, but product availability can differ. Emerging markets are more sensitive to affordability and may favor human insulin or locally manufactured alternatives.
Key Takeaways
- NovoLog Mix 50/50 is a mature insulin aspart premix marketed by Novo Nordisk.
- It contains equal proportions of rapid-acting insulin aspart and intermediate-acting insulin aspart protamine suspension.
- FDA approval was granted under NDA 021551 in 2007.
- Novo Nordisk does not disclose product-specific revenue or profit.
- The product is unlikely to be a meaningful growth contributor relative to Ozempic, Wegovy, and other GLP-1 products.
- Core composition exclusivity is no longer the principal barrier to competition.
- Formulation, manufacturing, device, and regulatory issues remain relevant.
- Biosimilar or follow-on insulin competition presents moderate long-term erosion risk.
- No major product-specific patent litigation or identified public Paragraph IV challenge is documented in the cited sources.
- The commercial outlook is stable to declining, with continued demand but limited pricing power and low growth.
FAQs
Is NovoLog Mix 50/50 being discontinued?
No discontinuation is established by the cited FDA materials. Product availability can vary by presentation, wholesaler, payer, and geography.
Is NovoLog Mix 50/50 interchangeable with NovoLog Mix 70/30?
No. The two products have different rapid-acting and protamine ratios and should not be treated as automatically interchangeable.
Is NovoLog Mix 50/50 a biosimilar?
No. NovoLog Mix 50/50 is Novo Nordisk’s original approved premixed insulin aspart product, not a biosimilar version of another insulin.
Can a pharmacy automatically substitute a future competitor for NovoLog Mix 50/50?
Only if the competing product receives the relevant FDA designation and substitution is permitted under applicable state law and payer rules.
Does NovoLog Mix 50/50 have meaningful patent value for licensing?
Its value is likely limited as a standalone patent asset. Commercial value would depend more on manufacturing know-how, regulatory history, device rights, supply capacity, and portfolio or market-access arrangements.
References
-
U.S. Food and Drug Administration. (2007). NovoLog Mix 50/50 prescribing information, NDA 021551. FDA.
-
U.S. Food and Drug Administration. (2020). Transition of insulin products and other biological products from the Federal Food, Drug, and Cosmetic Act to the Public Health Service Act. FDA.
-
U.S. Food and Drug Administration. (n.d.). Purple Book: Database of licensed biological products. FDA.
-
Novo Nordisk A/S. (2025). Annual report 2024. Novo Nordisk.
